Jove
Visualize
联系我们

相关概念视频

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

947
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
947
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

891
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
891
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

822
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
822
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

635
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
635
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

744
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
744

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Time trends in strategies for postoperative Crohn's disease management and long-term surgical recurrence: ENEIDA registry data.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

TIME-trend and forecasting of the economic impact of inflammatory bowel disease in Catalonia: a population-based analysis.

Journal of medical economics·2026
Same author

Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU.

Therapeutic advances in gastroenterology·2026
Same author

Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry.

Inflammatory bowel diseases·2026
Same author

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Alimentary pharmacology & therapeutics·2026
Same author

Risk of symptomatic leishmaniasis in patients with inflammatory bowel disease receiving biologic therapy in an endemic Mediterranean region: a population-based case-control study.

Journal of Crohn's & colitis·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jan 14, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.5K

结核病和炎症性肠道疾病.

Lucía Madero1, Iria Bastón2, Eduard Brunet-Mas3

  • 1Hospital General Dr. Balmis, Alicante, España; Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, España.

Gastroenterologia y hepatologia
|October 16, 2025
PubMed
概括

接受免疫抑制剂的炎症性肠病 (IBD) 患者面临更高的结核病 (TB) 风险. 在治疗前对潜伏结核病感染 (LTBI) 的查至关重要,以防止重新激活并安全指导治疗.

关键词:
生物制剂 生物制剂 生物制剂生物学的生物.克里巴多 (Cribado) 是一个字母.患有炎症性肠道疾病的人.伊格拉 (IGRA) 是一个免疫抑制是一种免疫抑制.炎症性肠病是一种炎症性肠病.免疫抑制是一种免疫抑制.在 PPDPD 的情况下,PPD 是 PPD.查检查 查检查 查检查这是一个治疗方法.治疗方法 治疗方法结核病是一种疾病.

更多相关视频

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

3.1K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

17.4K

相关实验视频

Last Updated: Jan 14, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.5K
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

3.1K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

17.4K

科学领域:

  • 胃肠病学 胃肠病学
  • 传染性疾病 传染性疾病
  • 免疫学 免疫学 免疫学

背景情况:

  • 炎症性肠病 (IBD) 包括性结肠炎和克罗恩病.
  • 肠胃炎症患者,特别是那些接受抗TNF药物等免疫抑制疗法的患者,患结核病 (TB) 的风险较高.
  • 结核病再激活的风险受免疫抑制药物的类型的影响,药物的组合可能会增加这种风险.

研究的目的:

  • 要突出患有炎症性肠道疾病的患者肺结核风险增加.
  • 强调在开始IBD患者免疫抑制疗法之前对潜伏结核感染 (LTBI) 进行查的必要性.
  • 在该患者群体中提供关于LTBI和活跃结核病的诊断方法和管理策略的指导.

主要方法:

  • 审查有关IBD患者结核病风险的当前指南和文献.
  • 讨论LTBI的诊断方式,包括结核素皮肤测试 (TST) 和干扰素释测试 (IGRA).
  • 考虑像胸部X射线等成像技术以及LTBI和活跃结核病的管理协议.

主要成果:

  • 针对IBD的免疫抑制疗法,包括抗TNF药物,免疫调节剂,抗整体素,IL-12/23抑制剂和JAK抑制剂,与结核病复激活的变化风险有关.
  • 建议在IBD诊断或先进治疗之前对LTBI进行查,对于免疫受损的个人建议进行双重测试.
  • 在免疫抑制之前建议对LTBI进行化疗预防;活性结核病需要停止治疗和抗结核疗法.

结论:

  • 潜伏结核病感染的积极查和管理对于炎症性肠病患者的安全治疗至关重要.
  • 应仔细考虑免疫抑制疗法,根据个体患者的因素进行风险分层和潜在的重新引入.
  • 活疫苗,如BCG,在接受免疫抑制治疗的IBD患者中是禁忌的.